vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and SuperCom Ltd (SPCB). Click either name above to swap in a different company.
SuperCom Ltd is the larger business by last-quarter revenue ($14.2M vs $9.5M, roughly 1.5× Cellectis S.A.). SuperCom Ltd runs the higher net margin — 37.5% vs -265.9%, a 303.4% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs -1.5%). Cellectis S.A. produced more free cash flow last quarter ($27.6M vs $-3.6M).
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
Super.com is a technology company headquartered in San Francisco and co-founded by Hussein Fazal and Henry Shi. The company provides financial services, including reward programs and travel bookings.
CLLS vs SPCB — Head-to-Head
Income Statement — Q2 FY2024 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $14.2M |
| Net Profit | $-25.3M | $5.3M |
| Gross Margin | — | 61.2% |
| Operating Margin | -181.1% | 16.3% |
| Net Margin | -265.9% | 37.5% |
| Revenue YoY | 375.0% | -1.5% |
| Net Profit YoY | -51.9% | 79.5% |
| EPS (diluted) | $-0.28 | $1.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | — | $14.2M | ||
| Q2 24 | $9.5M | $14.4M | ||
| Q3 23 | $1.6M | — | ||
| Q2 23 | $2.0M | $14.1M | ||
| Q2 22 | $2.7M | $6.3M |
| Q2 25 | — | $5.3M | ||
| Q2 24 | $-25.3M | $3.0M | ||
| Q3 23 | $-17.5M | — | ||
| Q2 23 | $-16.6M | $-2.6M | ||
| Q2 22 | $-19.5M | $-5.2M |
| Q2 25 | — | 61.2% | ||
| Q2 24 | — | 52.3% | ||
| Q3 23 | — | — | ||
| Q2 23 | 97.3% | 27.2% | ||
| Q2 22 | 87.9% | 41.8% |
| Q2 25 | — | 16.3% | ||
| Q2 24 | -181.1% | 7.7% | ||
| Q3 23 | -1258.1% | — | ||
| Q2 23 | -1180.5% | -12.2% | ||
| Q2 22 | -1003.0% | -49.9% |
| Q2 25 | — | 37.5% | ||
| Q2 24 | -265.9% | 20.6% | ||
| Q3 23 | -1064.1% | — | ||
| Q2 23 | -831.6% | -18.3% | ||
| Q2 22 | -714.4% | -82.4% |
| Q2 25 | — | $1.32 | ||
| Q2 24 | $-0.28 | $1.19 | ||
| Q3 23 | $-0.31 | — | ||
| Q2 23 | $-0.20 | $-10.66 | ||
| Q2 22 | $-0.42 | $-1.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $15.0M |
| Total DebtLower is stronger | — | $23.6M |
| Stockholders' EquityBook value | $148.6M | $37.3M |
| Total Assets | $407.1M | $65.5M |
| Debt / EquityLower = less leverage | — | 0.63× |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $15.0M | ||
| Q2 24 | $149.0M | $5.7M | ||
| Q3 23 | — | — | ||
| Q2 23 | $84.4M | $1.1M | ||
| Q2 22 | $129.4M | $2.9M |
| Q2 25 | — | $23.6M | ||
| Q2 24 | — | $29.2M | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $32.9M | ||
| Q2 22 | — | $32.3M |
| Q2 25 | — | $37.3M | ||
| Q2 24 | $148.6M | $13.8M | ||
| Q3 23 | $76.1M | — | ||
| Q2 23 | $96.6M | $3.5M | ||
| Q2 22 | $180.5M | $3.7M |
| Q2 25 | — | $65.5M | ||
| Q2 24 | $407.1M | $49.6M | ||
| Q3 23 | $209.7M | — | ||
| Q2 23 | $227.7M | $40.8M | ||
| Q2 22 | $320.9M | $42.7M |
| Q2 25 | — | 0.63× | ||
| Q2 24 | — | 2.11× | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 9.49× | ||
| Q2 22 | — | 8.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $-2.2M |
| Free Cash FlowOCF − Capex | $27.6M | $-3.6M |
| FCF MarginFCF / Revenue | 290.5% | -25.3% |
| Capex IntensityCapex / Revenue | 13.2% | 10.0% |
| Cash ConversionOCF / Net Profit | — | -0.41× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-14.0M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $-2.2M | ||
| Q2 24 | $28.9M | $-950.0K | ||
| Q3 23 | — | — | ||
| Q2 23 | $-47.4M | $-3.4M | ||
| Q2 22 | $-60.2M | $-4.1M |
| Q2 25 | — | $-3.6M | ||
| Q2 24 | $27.6M | $-1.6M | ||
| Q3 23 | — | — | ||
| Q2 23 | $-47.9M | $-4.5M | ||
| Q2 22 | $-61.7M | $-4.4M |
| Q2 25 | — | -25.3% | ||
| Q2 24 | 290.5% | -10.8% | ||
| Q3 23 | — | — | ||
| Q2 23 | -2391.4% | -31.5% | ||
| Q2 22 | -2266.7% | -70.4% |
| Q2 25 | — | 10.0% | ||
| Q2 24 | 13.2% | 4.2% | ||
| Q3 23 | — | — | ||
| Q2 23 | 24.1% | 7.4% | ||
| Q2 22 | 56.6% | 4.4% |
| Q2 25 | — | -0.41× | ||
| Q2 24 | — | -0.32× | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
